Bone Biologics Corporation
NASDAQ Capital MarketTotal Valuation
Bone Biologics Corporation carries a market capitalization of 1.60M, placing it among publicly traded companies globally. Its enterprise value stands at -4.53M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.60M |
| Enterprise Value | -4.53M |
Share Statistics
Bone Biologics Corporation currently has 1.80M shares outstanding.
| Shares Outstanding | 1.80M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Bone Biologics Corporation maintains a current ratio of 16.09, meaning it holds 16.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 16.09 |
| Quick Ratio | 14.67 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -70.21 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Bone Biologics Corporation's stock has declined approximately -34% over the past 52 weeks. The 50-day moving average sits at 15.80, while the 200-day moving average is 18.10.
| Beta (5Y) | N/A |
| 52-Week Price Change | -34% |
| 50-Day Moving Average | 15.80 |
| 200-Day Moving Average | 18.10 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -3.00M, while operating income came in at -3.00M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -3.00M |
| Pretax Income | -2.86M |
| Net Income | -2.86M |
| EBITDA | -3.00M |
| EBIT | -3.00M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Total book value stands at -88.89M, with working capital of 4.67M providing operational flexibility.
| Cash & Cash Equivalents | 4.53M |
| Total Debt | N/A |
| Net Debt | -4.53M |
| Equity (Book Value) | -88.89M |
| Book Value Per Share | N/A |
| Working Capital | 4.67M |
Cash Flow
Bone Biologics Corporation produced -2.57M in operating cash flow over the past twelve months.
| Operating Cash Flow | -2.57M |
| Capital Expenditures | N/A |
| Free Cash Flow | -2.57M |
| FCF Per Share | N/A |
Stock Splits
Bone Biologics Corporation's most recent stock split took place on June 10, 2025 with a 6:1 split ratio.
| Last Split Date | 6/10/2025 |
| Split Ratio | 6:1 |
Scores
Bone Biologics Corporation posts an Altman Z-Score of -25.86, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -25.86 |